Béranger Lueza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1628594/publications.pdf

Version: 2024-02-01

10	243	7	8
papers	citations	h-index	g-index
11	11	11	533
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 66-73.e6.	2.6	19
2	Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer, 2017, 112, 10-15.	2.0	3
3	Extrapolation of Survival Curves from Cancer Trials Using External Information. Medical Decision Making, 2017, 37, 353-366.	2.4	48
4	Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Annals of Oncology, 2016, 27, 1818-1828.	1.2	88
5	Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. BMC Medical Research Methodology, 2016, 16, 37.	3.1	28
6	Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study. PLoS ONE, 2016, 11, e0150032.	2.5	13
7	Reply to V.P. RetÃ'l et al, D. Gauchan et al, and C. Rahilly-Tierney et al. Journal of Clinical Oncology, 2015, 33, 1629-1630.	1.6	O
8	Cost Effectiveness of Molecular Profiling for Adjuvant Decision Making in Patients With Node-Negative Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3513-3519.	1.6	28
9	Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non–Small-Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2013, 8, 1295-1307.	1.1	16
10	Abstract B45: Upfront genomic testing in non-small cell lung cancer (NSCLC) patients: Preliminary result of the MSN study. Clinical Cancer Research, 2012, 18, B45-B45.	7.0	0